Regulator G protein Signaling (RGS) proteins are critical components of the intracellular signaling pathways that mediate the effects of G protein-coupled receptors (GPCRs). Upon activation, GPCRs have conformational changes that allow the coupling and subsequent activation of the G-protein heterotrimeric complex (α, β, and γ); it is at this point when the RGS proteins play a key role in the deactivation of the alpha subunit contributing to the termination of the G protein-mediated signaling cascades[1, 2].
RGS proteins are a family with around 20 members characterized by the presence of a conserved RGS-homology (RH) domain. This domain contains the catalytic core that catalyzes the hydrolysis of guanosine triphosphate (GTP) to guanosine diphosphate of the G protein α subunit promoting the switch from activated to an inactivated state. In addition to the RGS domain, RGS proteins also contain a range of other structural motifs that are critical for their function, including the G protein-binding domain, the DEP (Dishevelled, Egl-10 and Pleckstrin domain) domain, and the GoLoco motif[2, 3].
Role of RGS proteins in regulating GPCR signaling:
Recent studies have revealed that the interaction between RGS proteins and GPCRs is mediated by a range of structural motifs, including the G protein-binding (GB) and the RGS domains. The interaction between RGS proteins and GPCRs is highly specific and tightly regulated; mutations in the RGS domain and other structural motifs have been shown to alter the specificity and potency of the RGS-GPCR interaction.
As negative regulators of GPCR signaling, RGS proteins play a critical role in regulating the duration and amplitude of GPCR signaling. For example, μ opioid receptor (MOR) interacts with Gαi/o and Gαz subunits, which have a slow enzymatic GTPase activity requiring the action of RGSs proteins. RGSs bind to GTP-bound Gα to accelerate GTP hydrolysis reducing the activity of the Gα subunit and resulting in negative regulation of MOR downstream signaling[3, 4].
Besides the differences in their structural complexity, some members of the RGS family are selective for certain GPCRs, as a proof RGS4 which is expressed in the brain, has been shown to modulate dopamine signaling by specifically regulating the activity of the dopamine D2 receptor; enhancing the activity of the G protein that is coupled to the receptor and leading to a decrease in dopamine signaling[4, 5].
Another signaling pathway related to RGS4 involves the regulation of the immune response. RGS4 is expressed in various immune cells, including T cells and B cells, and has been shown to modulate immune cell activation and cytokine production. RGS4 acts as a negative regulator of T cell activation, and its expression is upregulated in response to T cell activation.
Implications of RGS protein dysregulation in disease:
The Dysregulation of RGS proteins has been implicated in a range of diseases, including cardiovascular disease, pain, hypertension, and cancer. In cardiovascular disease, RGS proteins play a critical role in regulating blood pressure and vascular function. Relating to pain, RGS4 in pain regulation is a topic of increasing interest because it has been identified as a key player in the modulation of nociception. In hypertension, dysregulation of RGS proteins has been shown to contribute to the pathogenesis of the disease. While in cancer, RGS proteins are involved in regulating cell proliferation and survival.
In conclusion, RGS proteins are essential modulators for the GPCR signaling mediated by G proteins, which play a crucial role in regulating a range of physiological processes. The dysregulation of these proteins has been implicated in a range of diseases, and understanding the mechanisms of these complex molecules is crucial for developing effective therapies.
1. Tesmer, J.J., et al., Structure of RGS4 bound to AlF4--activated G(i alpha1): stabilization of the transition state for GTP hydrolysis. Cell, 1997. 89(2): p. 251-61.
2. Senese, N.B., et al., Regulator of G-Protein Signaling (RGS) Protein Modulation of Opioid Receptor Signaling as a Potential Target for Pain Management. Front Mol Neurosci, 2020. 13: p. 5.
3. Hollinger, S. and J.R. Hepler, Cellular regulation of RGS proteins: modulators and integrators of G protein signaling. Pharmacol Rev, 2002. 54(3): p. 527-59.
4. Wang, Q., L.Y. Liu-Chen, and J.R. Traynor, Differential modulation of mu- and delta-opioid receptor agonists by endogenous RGS4 protein in SH-SY5Y cells. J Biol Chem, 2009. 284(27): p. 18357-67.
5. Zhuang, Y., et al., Structural insights into the human D1 and D2 dopamine receptor signaling complexes. Cell, 2021. 184(4): p. 931-942.e18.
6. Wang, D., The essential role of G protein-coupled receptor (GPCR) signaling in regulating T cell immunity. Immunopharmacol Immunotoxicol, 2018. 40(3): p. 187-192.
7. Avrampou, K., et al., RGS4 Maintains Chronic Pain Symptoms in Rodent Models. J Neurosci, 2019. 39(42): p. 8291-8304.
8. Hu, Y., et al., Identification of a five-gene signature of the RGS gene family with prognostic value in ovarian cancer. Genomics, 2021. 113(4): p. 2134-2144.